

## Nanexa announces exercise of warrants

Nanexa AB (publ) ("Nanexa" or the "Company") today announces the exercise of warrants issued in connection with the Company's directed issue of units, which was resolved upon by the Board of Directors on 24 January 2025. The directed issue consisted of units in two tranches, of which the first tranche was issued pursuant to the authorization from the Annual General Meeting held on 15 May 2024, and the second tranche was approved by the Extraordinary General Meeting on 13 February 2025. In connection with the directed issue, the Company also entered into loan agreements, whereby additional warrants were issued to the lenders as part of the overall financing solution (jointly the "Warrants"). All Warrants across the various tranches have now been exercised. In total, 27,878,788 Warrants have been exercised for the subscription of 27,878,788 new shares in the Company at a subscription price of SEK 2 per share. Through the exercise of the Warrants, Nanexa receives approximately SEK 55.7 million in total before transaction costs.

### Background

The exercise period for the Warrants ran from 18 February 2025 up to and including 31 March 2026. The subscription price for exercising the Warrants was previously fixed at SEK 2 per share.

A total of 27,878,788 Warrants were exercised for the subscription of an equal number of shares in the Company. As the Company has previously announced, approximately 15,000,000 Warrants had been exercised for the subscription of shares up to and including 16 March 2026. Subsequently, the remaining Warrants have been exercised, meaning that all 27,878,788 Warrants have now been exercised in their entirety.

### Number of shares and share capital

Through the exercise of the Warrants, the number of shares in Nanexa increases to 184,786,535, and the share capital increases to approximately SEK 23,915,324.25.

### Advisors

Zonda Partners is acting as Sole Global Coordinator and Bookrunner in connection with the directed issue. Advokatfirman Lindahl KB is acting as legal advisor to the Company.

### For additional information, please contact:

---

David Westberg – CEO, Nanexa AB (publ)  
Phone: +46 70 942 83 03  
Email: [david.westberg@nanexa.se](mailto:david.westberg@nanexa.se)  
[www.nanexa.com](http://www.nanexa.com)

The company's Certified Adviser is Tapper Partners AB.

---

## About Nanexa AB (publ)

---

Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company's proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of 'super generic' formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others.

Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

## Attachments

---

[Nanexa announces exercise of warrants](#)